N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors
| Title: | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors |
|---|---|
| Patent Number: | 8,084,442 |
| Publication Date: | December 27, 2011 |
| Appl. No: | 11/914183 |
| Application Filed: | May 12, 2006 |
| Abstract: | The present invention provides a pyrrolidine compound of General Formula (1) [chemical expression included] or a salt thereof, wherein R101 and R102 are each independently a phenyl group or a pyridyl group, the phenyl group or the pyridyl group may have one or more substituents selected from halogen atoms and lower alkyl groups optionally substituted with one or more halogen atoms, etc. The pyrrolidine compound or a salt thereof of the present invention is usable to produce a pharmaceutical preparation having a wider therapeutic spectrum and being capable of exhibiting sufficient therapeutic effects after short-term administration. |
| Inventors: | Kurimura, Muneaki (Tokushima, JP); Taira, Shinichi (Tokushima, JP); Tomoyasu, Takahiro (Tokushima, JP); Ito, Nobuaki (Tokushima, JP); Tai, Kuninori (Tokushima, JP); Takemura, Noriaki (Tokushima, JP); Matsuzaki, Takayuki (Tokushima, JP); Menjo, Yasuhiro (Tokushima, JP); Miyamura, Shin (Tokushima, JP); Sakurai, Yohji (Tokushima, JP); Watanabe, Akihito (Tokushima, JP); Sakata, Yasuyo (Tokushima, JP); Masumoto, Takumi (Tokushima, JP); Akazawa, Kohei (Tokushima, JP); Sugino, Haruhiko (Tokushima, JP); Amada, Naoki (Tokushima, JP); Ohashi, Satoshi (Tokushima, JP); Shinohara, Tomoichi (Tokushima, JP); Sasaki, Hirofumi (Tokushima, JP); Morita, Chisako (Tokushima, JP); Yamashita, Junko (Tokushima, JP); Nakajima, Satoko (Tokushima, JP) |
| Assignees: | Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP) |
| Claim: | 1. A pyrrolidine compound of General Formula (1) [chemical expression included] or a salt thereof, wherein R 101 and R 102 are each independently the following group (1): (1) a phenyl group, and the group (1) may have one or more substituents selected from the following (1-1) to (1-36) on the aromatic ring: (1-1) halogen atoms, (1-2) lower alkylthio groups optionally substituted with one or more halogen atoms, (1-3) lower alkyl groups optionally substituted with one or more halogen atoms, (1-4) lower alkoxy groups optionally substituted with one or more halogen atoms, (1-5) nitro group, (1-6) lower alkoxycarbonyl groups, (1-7) amino groups optionally substituted with one or two lower alkyl groups, (1-8) lower alkylsulfonyl groups, (1-9) cyano group, (1-10) carboxy group, (1-11) hydroxy group, (1-12) thienyl groups, (1-13) oxazolyl groups, (1-14) naphthyl groups, (1-15) benzoyl group, (1-16) phenoxy groups optionally substituted with one to three halogen atoms on the phenyl ring, (1-17) phenyl lower alkoxy groups, (1-18) lower alkanoyl groups, (1-19) phenyl groups optionally substituted on the phenyl ring with one to five substituents selected from the group consisting of halogen atoms, lower alkoxy groups, cyano group, lower alkanoyl groups and lower alkyl groups, (1-20) phenyl lower alkyl groups, (1-21) cyano lower alkyl groups, (1-22) 5 to 7-membered saturated heterocyclic group-substituted sulfonyl groups, the heterocyclic group containing on the heterocyclic ring one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, (1-23) thiazolyl groups optionally substituted with one or two lower alkyl groups on the thiazole ring, (1-24) imidazolyl groups, (1-25) amino lower alkyl groups optionally substituted with one or two lower alkyl groups on the amino group, (1-26) pyrrolidinyl lower alkoxy groups, (1-27) isoxazolyl groups, (1-28) cycloalkylcarbonyl groups, (1-29) naphthyloxy groups, (1-30) pyridyl groups, (1-31) furyl groups, (1-32) phenylthio group, (1-33) oxo group, (1-34) 5 to 7-membered saturated heterocyclic groups containing one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, the heterocyclic group optionally being substituted with one to three substituents selected from the group consisting of oxo group; lower alkyl groups; lower alkanoyl groups; phenyl lower alkyl groups; phenyl groups optionally substituted on the phenyl ring with one to three members selected from the group consisting of halogen atoms and lower alkoxy groups; and pyridyl groups, (1-35) oxido group and (1-36) lower alkoxido groups, with the proviso that R 101 and R 102 are not simultaneously unsubstituted phenyl. |
| Claim: | 2. A pyrrolidine compound of General Formula (1) or a salt thereof according to claim 1 , wherein R 101 is (1) a phenyl group, and may have on the aromatic ring one to three substituents selected from the groups (1-1) to (1-36). |
| Claim: | 3. A pyrrolidine compound of General Formula (1) or a salt thereof according to claim 2 , wherein R 101 is (1) a phenyl group and may have on the aromatic ring one to three substituents selected from the group consisting of (1-1) halogen atoms and (1-3) lower alkyl groups optionally substituted with one to three halogen atoms. |
| Claim: | 4. A pyrrolidine compound of General Formula (1) or a salt thereof according to claim 3 , wherein R 102 is (1) a phenyl group, and the group (1), may have on the aromatic ring one to three substituents selected from the groups (1-1) to (1-36). |
| Claim: | 5. A pyrrolidine compound of General Formula (1) or a salt thereof according to claim 4 , wherein R 101 is a monohalophenyl group, a dihalophenyl group or a phenyl group substituted with one halogen atom and one lower alkyl group, R 101 is (1) a phenyl group, and the group (1) may have on the aromatic ring one or two substituents selected from the group consisting of (1-1) halogen atoms, (1-3) lower alkyl groups optionally substituted with one or more halogen atoms, and (1-9) cyano group. |
| Claim: | 6. A pyrrolidine compound of General Formula (1) or a salt thereof according to claim 5 selected from the group consisting of: (4-chlorophenyl)phenyl-(S)-pyrrolidin-3-ylamine, (4-fluorophenyl)phenyl-(S)-pyrrolidin-3-ylamine, (3,4-difluorophenyl)phenyl-(S)-pyrrolidin-3-ylamine, bis-(4-fluorophenyl)-(S)-pyrrolidin-3-ylamine, (3,4-difluorophenyl)-(4-fluorophenyl)-(S)-pyrrolidin-3-ylamine, (3-chloro-4-fluorophenyl)-(S)-pyrrolidin-3-yl-p-tolylamine, 4-[(S)-(4-fluoro-3-methylphenyl)pyrrolidin-3-ylamino]-benzonitrile, and bis-(3-fluorophenyl)-(S)-pyrrolidin-3-ylamine. |
| Claim: | 7. A pharmaceutical composition comprising a pyrrolidine compound of General Formula (1) or a salt thereof according to claim 1 as an active ingredient and a pharmaceutically acceptable carrier. |
| Claim: | 8. A method of treating disorders caused by reduced neurotransmission of serotonin, norepinephrine or dopamine, comprising administering a therapeutically effective amount of a pyrrolidine compound of General Formula (1) or a salt thereof according to claim 1 to a human or an animal in need thereof wherein the disorder is depression. |
| Claim: | 9. A process for producing a pyrrolidine compound of General Formula (1): [chemical expression included] or a salt thereof, wherein R 101 and R 102 are defined above in claim 1 , the process comprising (1) subjecting a compound of General Formula (2) [chemical expression included] wherein R 101 and R 102 are as defined above in claim 1 , and R 112 is an amino-protecting group to an elimination reaction to remove the amino protecting group. |
| Current U.S. Class: | 514/63 |
| Patent References Cited: | 3433802 March 1969 Dawson et al. 3509171 April 1970 Welstead, Jr. et al. 3577440 May 1971 Lunsford et al. 4254135 March 1981 Walsh et al. 1164828 September 1969 1 173 373 December 1969 1523631 September 1976 2 295 387 May 1996 98/28270 July 1998 01/83434 November 2001 02/94794 November 2002 2004/110995 December 2004 2004/111003 December 2004 2005/000305 January 2005 2005/000811 January 2005 2005/047251 May 2005 |
| Other References: | Pelcman et al., caplus an 1998:479507. cited by examiner Alzheimer's Disease Treatment Phases, http://www.alzheimerstreatment.org/treatment/disease-treatment.htm (2008). cited by examiner Alzheimer's Drugs, Consumer Reports Best Buy Drugs (p. 1-5) (2006). cited by examiner Kurimura et al., caplus an 2008:733525. cited by examiner Office Action dated Oct. 19, 2009 as issued in European Patent Application No. 06756356.9. cited by other Sadanori Miura, “Rinshoseishinyakuri”, Japanese Journal of Clinical Psychopharmacology, 2000, vol. 3, pp. 311-318. cited by other Phil Skolnick, “Antidepressants for the new millennium”, European Jounal of Pharmacology 375, 1999, pp. 31-40. cited by other Office Action dated Oct. 16, 2009 as issued in European Patent Application No. 06756356.9. cited by other Examination Report for Australian Patent Application No. 2010201952, dated Jun. 2, 2011. cited by other |
| Primary Examiner: | Loewe, Sun Jae |
| Attorney, Agent or Firm: | Sughrue Mion, PLLC |
| Accession Number: | edspgr.08084442 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|